Predictive Oncology issues letter to shareholders

Predictive Oncology (POAI) issued the following shareholder update: “The past several weeks have been particularly noteworthy and productive at Predictive Oncology, and I wanted to take this opportunity to provide a brief recap of recent developments… By testing multiple chemotherapies on a patients’ cancer cells before treatment selection, ChemoFx helps determine which chemotherapies are more likely to be effective on the tumor and which are less likely to provide benefit to the patient… As we look to develop the next generation of ChemoFx, the Company anticipates the ability to extend beyond gynecological cancers, into other tumor types, including breast, colon and lung… Collectively, these capabilities directly support the Company’s AI-driven drug discovery initiatives by generating high-quality data that feeds into predictive models and supports biomarker discovery, companion diagnostics, and clinical trial design… In parallel with our ChemoFx commercialization activities, we remain focused on our drug and biomarker discovery and drug repurposing initiatives that we will advance either independently or in collaboration with strategic partners. Building on the success of the Magee study, we identified novel ovarian cancer biomarkers linked to patient survival and drug response using advanced deep learning methods… To efficiently and effectively execute on the US expansion and EU launch of ChemoFx, and simultaneously pursue the emerging opportunities utilizing our core AI and machine learning capabilities, we were very pleased to have recently announced a $10 million Securities Purchase Agreement with Yorkville Advisors Global, LP… In closing, we continue to methodically take steps to create a solid foundation from which to drive meaningful and sustained growth in 2026 and beyond.”